NASDAQ:BOLD - Audentes Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $59.21 -0.09 (-0.15 %) (As of 12/5/2019 04:00 PM ET) Add Compare Today's Range$59.12Now: $59.21▼$59.3550-Day Range$25.50MA: $29.57▼$59.2752-Week Range$17.95Now: $59.21▼$59.48Volume3.38 million shsAverage Volume632,707 shsMarket Capitalization$2.71 billionP/E RatioN/ADividend YieldN/ABeta1.77 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BOLD Previous Symbol CUSIPN/A CIK1628738 Webhttp://www.audentestx.com/ Phone415-818-1001Debt Debt-to-Equity RatioN/A Current Ratio12.80 Quick Ratio12.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($7.48) per share Price / Book-7.92Profitability EPS (Most Recent Fiscal Year)($3.40) Net Income$-128,820,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-38.00%Miscellaneous Employees207 Outstanding Shares45,783,000Market Cap$2.71 billion Next Earnings Date2/26/2020 (Estimated) OptionableOptionable Receive BOLD News and Ratings via Email Sign-up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:BOLD Rates by TradingView Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions What is Audentes Therapeutics' stock symbol? Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD." How were Audentes Therapeutics' earnings last quarter? Audentes Therapeutics Inc (NASDAQ:BOLD) released its earnings results on Thursday, November, 7th. The biotechnology company reported ($1.00) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.07) by $0.07. During the same period last year, the firm earned ($0.97) earnings per share. View Audentes Therapeutics' Earnings History. When is Audentes Therapeutics' next earnings date? Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Audentes Therapeutics. What price target have analysts set for BOLD? 17 analysts have issued 12-month price objectives for Audentes Therapeutics' stock. Their forecasts range from $10.00 to $60.00. On average, they expect Audentes Therapeutics' stock price to reach $47.46 in the next twelve months. This suggests that the stock has a possible downside of 19.8%. View Analyst Price Targets for Audentes Therapeutics. What is the consensus analysts' recommendation for Audentes Therapeutics? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 14 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Audentes Therapeutics. What are Wall Street analysts saying about Audentes Therapeutics stock? Here are some recent quotes from research analysts about Audentes Therapeutics stock: 1. According to Zacks Investment Research, "Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. " (11/8/2019) 2. HC Wainwright analysts commented, "Our $44 (raised from $33) price target on shares of Audentes is based on a 12-year DCF-based, sum-of-the-parts analysis, which includes AT132 being developed for XLMTM and AT845, that is being advanced as a one-and-done approach for Pompe disease. Note, our prior $33 target, did not reflect AT-845. Our DCF is driven by a: beta of 1.25, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.0%, and tax rate of 15% beginning in FY 2028." (3/18/2019) 3. Mizuho analysts commented, "We spoke with management following yesterday’s regulatory update on AT132. Audentes held an encouraging first meeting with regulators and will continue to enroll patients in the high-dose cohort 2. Six-month biopsy data from this high- dose cohort is expected in 2Q19 and will help inform an optimal dose of AT132. Audentes then plans to submit an updated data package to the FDA, after which a second FDA meeting will be held; we anticipate this could happen in 3Q19 and we expect minutes from this meeting will provide more clarity around the pathway to a BLA filing for AT132. This could be an important catalyst in 2019. In the meantime, the next data update will be ASGCT." (2/1/2019) Has Audentes Therapeutics been receiving favorable news coverage? Press coverage about BOLD stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Audentes Therapeutics earned a news impact score of -1.6 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Audentes Therapeutics. Who are some of Audentes Therapeutics' key competitors? Some companies that are related to Audentes Therapeutics include Qiagen (QGEN), BIO-TECHNE (TECH), Moderna (MRNA), argenx (ARGX), BioNTech (BNTX), China Biologic Products (CBPO), Repligen (RGEN), bluebird bio (BLUE), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA) and Halozyme Therapeutics (HALO). What other stocks do shareholders of Audentes Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer LP Unit (ET), Cisco Systems (CSCO), Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Gilead Sciences (GILD), QUALCOMM (QCOM), AT&T (T), Thermo Fisher Scientific (TMO) and Amgen (AMGN). Who are Audentes Therapeutics' key executives? Audentes Therapeutics' management team includes the folowing people: Mr. Matthew R. Patterson, Co-Founder, Chairman & CEO (Age 47)Ms. Natalie C. Holles, Pres & COO (Age 46)Mr. Thomas P. Soloway, Exec. VP & CFO (Age 52)Dr. John T. Gray, Sr. VP & Chief Scientific Officer (Age 56)Mr. Andrew H. Chang, Director of Investor Relations When did Audentes Therapeutics IPO? (BOLD) raised $75 million in an initial public offering on Wednesday, July 20th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Audentes Therapeutics' major shareholders? Audentes Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Redmile Group LLC (6.47%), Great Point Partners LLC (5.43%), State Street Corp (3.69%), Orbimed Advisors LLC (3.47%), Millennium Management LLC (1.69%) and Point72 Asset Management L.P. (0.53%). Company insiders that own Audentes Therapeutics stock include David Nagler, John T Gray, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Institutional Ownership Trends for Audentes Therapeutics. Which institutional investors are selling Audentes Therapeutics stock? BOLD stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., State Street Corp, Orbimed Advisors LLC, SG Americas Securities LLC, Voloridge Investment Management LLC, Man Group plc, Redmile Group LLC and Great West Life Assurance Co. Can. Company insiders that have sold Audentes Therapeutics company stock in the last year include Louis G Lange, Matthew R Patterson and Suyash Prasad. View Insider Buying and Selling for Audentes Therapeutics. Which institutional investors are buying Audentes Therapeutics stock? BOLD stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Millennium Management LLC, State of New Jersey Common Pension Fund D, Squarepoint Ops LLC, Russell Investments Group Ltd., California Public Employees Retirement System, Dupont Capital Management Corp and Point72 Asset Management L.P.. View Insider Buying and Selling for Audentes Therapeutics. How do I buy shares of Audentes Therapeutics? Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Audentes Therapeutics' stock price today? One share of BOLD stock can currently be purchased for approximately $59.21. How big of a company is Audentes Therapeutics? Audentes Therapeutics has a market capitalization of $2.71 billion. The biotechnology company earns $-128,820,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 207 workers across the globe.View Additional Information About Audentes Therapeutics. What is Audentes Therapeutics' official website? The official website for Audentes Therapeutics is http://www.audentestx.com/. How can I contact Audentes Therapeutics? Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected] MarketBeat Community Rating for Audentes Therapeutics (NASDAQ BOLD)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 414 (Vote Outperform)Underperform Votes: 375 (Vote Underperform)Total Votes: 789MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe BOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOLD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/5/2019 by MarketBeat.com StaffFeatured Article: Understanding Specialty Certificates of Deposit
